Evidence map›Paper›PMID 36654521›Full record

SynthesisActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale2022

Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review.

Mario Turri-Zanoni, Gianluca Dalfino, Matt Lechner, Iacopo Dallan, Paolo Battaglia, Carla Facco, Francesca Franzi, Giacomo Gravante, Marco Ferrari, Dimitrios Terzakis and 9 more

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Sinonasal Sarcomas Management: An International Consensus Statement.International forum of allergy & rhinology · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 5 countries.

Mario Turri-ZanoniDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Gianluca DalfinoDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Matt LechnerUCL Cancer Institute, University College London; Head and Neck Centre, University College London Hospitals and Barts Health NHS Trust, London, UK.
Iacopo DallanENT Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Paolo BattagliaDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Carla FaccoDepartment of Pathology, ASST Sette Laghi, University of Insubria, Varese, Italy.
Francesca FranziDepartment of Pathology, ASST Sette Laghi, University of Insubria, Varese, Italy.
Giacomo GravanteDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Marco FerrariSection of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosciences, University of Padua, Azienda Ospedaliera di Padova, Padua, Italy.
Dimitrios TerzakisDepartment of Otorhinolaryngology-Head & Neck Surgery, Hygeia Hospital, Athens, Greece.
Amrita JayDepartment of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK.
Martin D ForsterUCL Cancer Institute, London, United Kingdom; Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Andrea Luigi AmbrosoliDepartment of Anesthesia and Intensive Care, Filippo Del Ponte Hospital, ASST Sette Laghi, Varese, Italy.
Maurizio BignamiHead and Neck Surgery & Forensic Dissection Research center (HNS&FDRc), Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Christos GeorgalasDepartment of Otorhinolaryngology-Head & Neck Surgery, Hygeia Hospital, Athens, Greece.
Philippe HermanDepartment of Otolaryngology, Lariboisière University Hospital, Paris Diderot University, APHP, Paris Sorbonne Cité, Paris, France.
Piero NicolaiSection of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosciences, University of Padua, Azienda Ospedaliera di Padova, Padua, Italy.
Valerie J LundRoyal National Throat, Nose and Ear Hospital, UCLH Foundation Trust, London, United Kingdom.
Paolo CastelnuovoDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
University of Insubria · ITHygeia Hospital · GRUniversity College London · GBAssistance Publique – Hôpitaux de Paris · FRAzienda Ospedale - Università Padova · ITAzienda Ospedaliera Universitaria Pisana · ITCRUK Lung Cancer Centre of Excellence · GBOspedale Filippo Del Ponte Varese · ITRoyal National Throat Nose and Ear Hospital · GBUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Biphenotypic sinonasal sarcoma (BSNS) is a rare low-grade cancer that was included from the 4th edition of WHO classification of head and neck tumours. The purpose of this study is to analyse clinical behaviour, pattern of recurrences and survival outcomes of this neoplasm. Methods: Retrospective review of patients affected by BSNS who were treated via an endoscopic-assisted approach in 6 European tertiary-care referral hospitals. Cases of BSNS described in literature since 2012 to date were fully reviewed, according to PRISMA guidelines. Results: A total of 15 patients were included. Seven patients were treated via an endoscopic endonasal approach, 4 with endoscopic transnasal craniectomy, and 4 via a cranio-endoscopic approach. Adjuvant treatment was delivered in 2 cases. After a mean follow-up of 27.3 months, systemic metastasis was observed in 1 case; the 5-year overall survival and disease-free survival rates were 100% and 80 ± 17.9%, respectively. Conclusions: BSNS is a locally aggressive tumour with a low recurrence rate and encouraging survival outcomes if properly treated with surgical resection and free margins followed by adjuvant radiotherapy for selected cases. Endoscopic-assisted surgery is safe and effective as an upfront treatment within a multidisciplinary care protocol.

Indexed as

Paranasal Sinus NeoplasmsSarcomaDisease-Free SurvivalHumansMulticenter Studies as TopicRetrospective Studiesanterior skull basebiphenotypic sarcomaendoscopic endonasal surgerylow-grade sarcomasinonasal cancer

Identifiers

PMID36654521
PMCPMC9853106
OpenAlexW4316468685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.